Brief: Abbisko Cayman Says Merck's Exercise Of Global Option For Pimicotinib
01/04/2025 02:27
April 1 (Reuters) - Abbisko Cayman Ltd 2256.HK: MERCK'S EXERCISE OF GLOBAL OPTION FOR PIMICOTINIB UNDER LICENSING AGREEMENT WITH OPTION EXERCISE FEE OF USD85.0 MILLION Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration